Viva Biotech Holdings (HK:1873)
:1873
Want to see HK:1873 full AI Analyst Report?
1873 Stock Chart & Stats
HK$1.76
-HK$0.01(-1.20%)
At close: 4:00 PM EST
HK$1.76
-HK$0.01(-1.20%)
Day’s Range― - ―
52-Week RangeHK$1.34 - HK$3.27
Previous CloseN/A
Volume129.00K
Average Volume (3M)10.31M
Market Cap
HK$3.07B
Enterprise ValueHK$2.88B
Total Cash (Recent Filing)HK$1.13B
Total Debt (Recent Filing)HK$1.33B
Price to Earnings (P/E)18.0
Beta2.14
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,129,882,300
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)0.99
Price to Sales (P/S)2.28
P/FCF Ratio44.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.17B
Bulls Say, Bears Say
Bulls Say
Integrated CRO Service Model With Venture PlatformViva's integrated discovery-stage CRO services create durable client stickiness across multiple R&D disciplines, raising switching costs versus niche providers. The venture/innovation platform diversifies revenue sources and adds upside through equity monetizations, providing structural optionality beyond fee-for-service work.
Stable Gross And Operating MarginsConsistent mid-30s gross margins and low-teens operating margins indicate persistent unit economics in discovery services. Stable margins support long-term earnings quality, enabling reinvestment in capabilities and buffering profit if revenues ebb, assuming client demand normalizes.
Improving Leverage And Equity BaseMaterial reduction in debt-to-equity to roughly one-third strengthens the balance sheet and financial flexibility. A larger equity base reduces refinancing risk and supports ongoing R&D investments or venture commitments, making the company more resilient to cyclical profitability swings.
Bears Say
Multi-year Revenue DeclineSustained top-line contraction, including an 8.3% drop in 2025, undermines scale economics and limits ability to leverage stable margins into higher profits. Continued revenue shrinkage pressures sales capacity, client diversification, and the funding available for strategic investments or venture commitments.
Weakening Free Cash Flow MomentumA ~59% YoY FCF drop in 2025 and prior uneven cash conversion signal volatile cash generation. Reduced FCF constrains organic investment, makes external funding more likely for growth or venture activities, and increases sensitivity to working-capital swings over the medium term.
Profitability Volatility Across The CycleAlthough profits returned in 2024–2025, prior multi-year losses show earnings are cyclical. This volatility reduces forecast reliability, heightens refinancing and dividend risk if margins or revenues slip, and makes sustaining improved credit metrics contingent on continued profit recovery.
Viva Biotech Holdings News
1873 FAQ
What was Viva Biotech Holdings’s price range in the past 12 months?
Viva Biotech Holdings lowest stock price was HK$1.34 and its highest was HK$3.27 in the past 12 months.
What is Viva Biotech Holdings’s market cap?
Viva Biotech Holdings’s market cap is HK$3.07B.
When is Viva Biotech Holdings’s upcoming earnings report date?
Viva Biotech Holdings’s upcoming earnings report date is Aug 31, 2026 which is in 102 days.
How were Viva Biotech Holdings’s earnings last quarter?
Viva Biotech Holdings released its earnings results on Mar 30, 2026. The company reported HK$0.051 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.051.
Is Viva Biotech Holdings overvalued?
According to Wall Street analysts Viva Biotech Holdings’s price is currently Undervalued.
Does Viva Biotech Holdings pay dividends?
Viva Biotech Holdings pays a Notavailable dividend of HK$0.01 which represents an annual dividend yield of N/A. See more information on Viva Biotech Holdings dividends here
What is Viva Biotech Holdings’s EPS estimate?
Viva Biotech Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viva Biotech Holdings have?
Viva Biotech Holdings has 2,129,882,300 shares outstanding.
What happened to Viva Biotech Holdings’s price movement after its last earnings report?
Viva Biotech Holdings reported an EPS of HK$0.051 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.785%.
Which hedge fund is a major shareholder of Viva Biotech Holdings?
Currently, no hedge funds are holding shares in HK:1873
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viva Biotech Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.01%
12-Months-Change
Fundamentals
Return on Equity
5.53%
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
1873 Stock 12 Month Forecast
Average Price Target
HK$4.00
▲(127.27% Upside)
Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Lepu Biopharma Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---